Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry

被引:81
作者
Williamson, JF
Coursey, BM
DeWerd, LA
Hanson, WF
Nath, R
Ibbott, G
机构
[1] Washington Univ, Med Ctr, Ctr Radiat Oncol, St Louis, MO 63110 USA
[2] Natl Inst Stand & Technol, Ionizing Radiat Div, Gaithersburg, MD 20899 USA
[3] Univ Wisconsin, Radiat Calibrat Labs, Madison, WI 53706 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[5] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA
[6] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA
关键词
brachytherapy; I-125; seeds; dosimetry; air-kerma strength; primary standard; dose-rate constant; Task Group 43;
D O I
10.1118/1.598570
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Dose calculations to patients undergoing implantation of I-125 interstitial brachytherapy sources are affected by two recent changes in low-energy seed dosimetry: (a) implantation of a new primary air-kerma strength standard at the National Institute of Standards and Technology (NIST) on 1 January 1999 and (b) publication of revised dose-rate distributions in AAPM's Task Group 43 Report. The guidance herein represents AAPM's recommendations for users of I-125 interstitial seed products marketed prior to 1 January 1999 (Nycomed Amersham models 6711 and 6702 and North American Scientific, Inc. models 3631 A/S and 3631 A/M. Implementation of Task Group 43 (TG43) I-125 dose calculations involves revising data stored in files of radiation treatment planning software and lowering the prescribed dose to be delivered to patients by as much as 15% to avoid modifying the dose actually delivered to patients. The magnitude of the dose prescription change depends on the dosimetry data used prior to TG43 and the implant geometry. Adapting to the revised NIST calibration standard requires the user to increase the dose-rate constant (or its equivalent by 11.5%) but does not require modification of the prescribed dose. Failure to correctly implement these modifications can result in 20% or even 30% errors. (C) 1999 American Association of Physicists in Medicine. [S0094-2405(99)02804-7].
引用
收藏
页码:570 / 573
页数:4
相关论文
共 9 条
[1]   Clinical impact of implementing the recommendations of AAPM task group 43 on permanent prostate brachytherapy using 125I [J].
Bice, WS ;
Prestidge, BR ;
Prete, JJ ;
Dubois, DF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (05) :1237-1241
[2]   Report of the ad hoc committee of the AAPM radiation therapy committee on 125I sealed source dosimetry [J].
Kubo, HD ;
Coursey, BM ;
Hanson, WF ;
Kline, RW ;
Seltzer, SM ;
Shuping, RE ;
Williamson, JF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (03) :697-702
[3]   PHYSICAL DOSIMETRY OF I-125 SEEDS OF A NEW DESIGN FOR INTERSTITIAL IMPLANT [J].
LING, CC ;
YORKE, ED ;
SPIRO, IJ ;
KUBIATOWICZ, D ;
BENNETT, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (11) :1747-1752
[4]   EXPOSURE STANDARDIZATION OF I125 SEEDS USED FOR BRACHYTHERAPY [J].
LOFTUS, TP .
JOURNAL OF RESEARCH OF THE NATIONAL BUREAU OF STANDARDS, 1984, 89 (04) :295-303
[5]   Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group No. 56 [J].
Nath, R ;
Anderson, LL ;
Meli, JA ;
Olch, AJ ;
Stitt, JA ;
Williamson, JF .
MEDICAL PHYSICS, 1997, 24 (10) :1557-1598
[6]   DOSIMETRY OF INTERSTITIAL BRACHYTHERAPY SOURCES - RECOMMENDATIONS OF THE AAPM RADIATION-THERAPY COMMITTEE TASK GROUP NO 43 [J].
NATH, R ;
ANDERSON, LL ;
LUXTON, G ;
WEAVER, KA ;
WILLIAMSON, JF ;
MEIGOONI, AS .
MEDICAL PHYSICS, 1995, 22 (02) :209-234
[7]  
Seltzer S, 1998, MED PHYS, V25, pA170
[8]   Evaluation of a new brachytherapy iodine-125 source by AAPM TG43 formalism [J].
Wallace, RE ;
Fan, JJ .
MEDICAL PHYSICS, 1998, 25 (11) :2190-2196
[9]  
Williamson J S, 1988, Reg Immunol, V1, P15